Rituximab exhibits a better safety profile when used as a first line of treatment for pemphigus vulgaris: A retrospective study

Aryanian, Zeinab; Balighi, Kamran; Daneshpazhooh, Maryam; Karamshahi, Emad; Hatami, Parvaneh; Goodarzi, Azadeh; Tajalli, Mahroo; Vance, Terrence M.

doi:10.1016/j.intimp.2021.107755

Cited by 31 publications

(37 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, the amount of depigmentation was determined according to previous studies. 15 Then, VASI score was calculated by the following formula: VASI=∑ S all body sites (hand units)×(residual depigmented). Severity of disease was determined based on VASI score as follows: mild (VASI: 0%-25%), moderate (VASI: 25%-50%), severe (VASI: 50%-75%) and serious involvement (VASI: 75%-100%).…”

Section: Materials and Methods Study Designmentioning

confidence: 99%

“…Severity of disease was determined based on VASI score as follows: mild (VASI: 0%-25%), moderate (VASI: 25%-50%), severe (VASI: 50%-75%) and serious involvement (VASI: 75%-100%). 15…”

Section: Materials and Methods Study Designmentioning

confidence: 99%

“…Moreover, patients were physically examined and Vitiligo Area Severity Index (VASI) score was calculated as follows: the extension of vitiligo lesions was calculated in terms of hand units which is considered as 1% of total body surface area. On the other hand, the amount of depigmentation was determined according to previous studies 15. Then, VASI score was calculated by the following formula: VASI=∑ S all body sites (hand units)×(residual depigmented).…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Metabolic Derangement in Patients with Vitiligo: A Cross-Sectional Study

Aryanian

Shirzadian

Farzaneh

et al. 2022

Journal of Investigative Medicine

Self Cite

View full text Add to dashboard Cite

Vitiligo is a pigmentary disorder resulting from progressive destruction of melanocytes in the skin. There is a growing body of evidence about higher risk of metabolic syndrome and dyslipidemia in some dermatoses including vitiligo. We aimed to evaluate lipid profile, leptin and C reactive protein (CRP) status among Iranian patients with vitiligo, compared with healthy controls and perused the relationship between abnormal values of these parameters with disease duration and physical characteristics of patients. 40 patients with vitiligo and 40 age-matched and sex-matched healthy controls were enrolled in the study. Data on weight, height, lipid profile, leptin and CRP values were recorded and compared. The mean values for nearly all study parameters (except for high-density lipoprotein) were significantly higher in patients with vitiligo, compared with healthy controls, irrespective of age and sex. We could not find any correlation between vitiligo and study parameters, regarding disease severity and extension of lesions; but in patients who have been suffering from vitiligo for more than 5 years, systolic blood pressure, diastolic blood pressure and CRP values were noted to be significantly higher (p<0.001, p=0.003 and p=0.03, respectively). In conclusion, screening of patients with vitiligo in regard to their lipid profile as well as blood pressure should be considered, especially in patients with longer disease duration or those who have other cardiovascular risk factors to prevent morbidity and mortality as a result of developing cardiovascular events.

show abstract

Section: Materials and Methods Study Designmentioning

confidence: 99%

“…Severity of disease was determined based on VASI score as follows: mild (VASI: 0%-25%), moderate (VASI: 25%-50%), severe (VASI: 50%-75%) and serious involvement (VASI: 75%-100%). 15…”

Section: Materials and Methods Study Designmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Metabolic Derangement in Patients with Vitiligo: A Cross-Sectional Study

Aryanian

Shirzadian

Farzaneh

et al. 2022

Journal of Investigative Medicine

Self Cite

View full text Add to dashboard Cite

show abstract

“…The authors of this study have focused on the immunologic aspects of various topics in dermatology and recently turned their focus on COVID-19-associated dermatologic topics (22)(23)(24)(25)(26)(27)(28) as an issue of great importance discussed in this paper. Since the vaccination of children was not started across the world until the last update of this review, vaccine-related cutaneous reactions in children should be dealt with in future studies.…”

Section: Covid-19-related Cutaneous Manifestations In Chil-mentioning

confidence: 99%

Cutaneous Manifestations of COVID-19 in Children: Practical Points for Clinicians

2022

Self Cite

View full text Add to dashboard Cite

: Coronavirus disease 2019 (COVID-19) in previously healthy children is more likely to be mild. However, COVID-19-related cutaneous manifestations in children can be categorized regarding their clinical manifestations. We searched PubMed, Google Scholar, and Scopus in this regard and examined all of the relevant papers published until June 28, 2021, with available full-texts. We found various mucocutaneous manifestations after COVID-19 infection and categorized them regarding their etiology: Induced directly by the virus itself or its immunologic response, treatment-related adverse events, post-vaccination rash, and lesions seen as an indirect consequence of the pandemic such as irritant dermatitis resulting from frequent hand washing or stress-induced worsening of some chronic dermatoses such as atopic dermatitis and psoriasis as a result of social isolation. Clinicians should be aware of these manifestations and advocate early isolation while encountering unexplained skin lesions to prevent infection from spreading.

show abstract

“…Immunotherapy is among the best treatment modalities regarding efficacy and safety in patients with many dermatoses 1–4 . Rituximab (RTX), an anti‐CD20 monoclonal antibody, has recently shown great promise in terms of its effectiveness and safety 5,6 …”

Section: Introductionmentioning

confidence: 99%

Multiple cycles of rituximab therapy for pemphigus: A group of patients with difficult‐ to‐treat disease or a consequence of late rituximab initiation?

Balighi

Hatami

Aboli

et al. 2021

Dermatologic Therapy

Self Cite

View full text Add to dashboard Cite

Pemphigus is a serious autoimmune disease with few appropriate therapeutic options. Although rituximab (RTX) has recently shown great promise in this regard, the best protocol of its administration is remains to be elucidated. This study aimed to evaluate the patients who need at least 3 cycles of treatment with RTX to identify hard-to-treat patients' characteristics, which might lead to consider more prompt protocols for treatment of them. A retrospective cross-sectional study was conducted on 45 patients with pemphigus vulgaris who received at least 3 cycles of RTX. Their demographic, clinical, and laboratory data as well as details of treatment protocol and final clinical situation of patients were evaluated. Totally, 45 patients (21 men and 24 women) with mean age of 44.33 years were included in this paper.Women were about 8 years older than men (mean age: 48.1 years versus 40.1 years, p: 0.011) and needed RTX approximately 2 years later in their course of disease (gap: 41.04 months vs. 14.85 months, p: 0.003). Buccal, truncal, and scalp regions were the most frequent sites of involvement respectively. A significant decrease in both anti-Dsg1, 3 was seen at last visit compared to baseline. However, the amount of this decrement was not significantly different between them (p: 0.083). Partial remission in 31.11%, complete remission in 24.44%, relapse in 15.56%, partial remission on treatment in 15.56% and complete remission on treatment in 13.33% were seen at the last follow-up session. RTX is an effective medication for PV even in patients with refractory disease and its therapeutic effect is increased with each subsequent cycle. Male gender, severe oral mucosal involvement on disease onset and extensive scalp and truncal lesions as first cutaneous manifestation of disease are more likely to be signs of refractory PV. Hence, it is reasonable to consider more prompt protocols for treatment of these cases. Moreover, late prescription of RTX during the course of disease might play a role in presence of more resistant form of disease.

show abstract

Rituximab exhibits a better safety profile when used as a first line of treatment for pemphigus vulgaris: A retrospective study

Cited by 31 publications

References 23 publications

Metabolic Derangement in Patients with Vitiligo: A Cross-Sectional Study

Metabolic Derangement in Patients with Vitiligo: A Cross-Sectional Study

Cutaneous Manifestations of COVID-19 in Children: Practical Points for Clinicians

Multiple cycles of rituximab therapy for pemphigus: A group of patients with difficult‐ to‐treat disease or a consequence of late rituximab initiation?

Contact Info

Product

Resources

About